TY - JOUR
T1 - Rheumatoid arthritis patients with low baseline Health Assessment Questionnaire scores have a risk of functional disability progression
T2 - a post hoc analysis of a nationwide longitudinal cohort in Japan
AU - and the Japanese RA Patients with RRP Study Group
AU - Sumiyoshi, Remi
AU - Hidaka, Toshihiko
AU - Koga, Tomohiro
AU - Okada, Akitomo
AU - Fukuda, Takaaki
AU - Ishii, Tomonori
AU - Ueki, Yukitaka
AU - Kodera, Takao
AU - Nakashima, Munetoshi
AU - Takahashi, Yuichi
AU - Honda, Seiyo
AU - Horai, Yoshiro
AU - Watanabe, Ryu
AU - Okuno, Hiroshi
AU - Aramaki, Toshiyuki
AU - Izumiyama, Tomomasa
AU - Takai, Osamu
AU - Miyashita, Taiichiro
AU - Kawashiri, Shin Ya
AU - Iwamoto, Naoki
AU - Ichinose, Kunihiro
AU - Tamai, Mami
AU - Nakamura, Hideki
AU - Origuchi, Tomoki
AU - Eguchi, Katsumi
AU - Kawakami, Atsushi
PY - 2020/11/1
Y1 - 2020/11/1
N2 - OBJECTIVES: To determine prognostic factors for the Health Assessment Questionnaire-Disability Index (HAQ-DI) progression in patients with rheumatoid arthritis (RA) in clinical practice. METHODS: We evaluated 388 biological disease-modifying anti-rheumatic drug (bDMARD)-naïve Japanese patients with RA with moderate to high disease activity at study entry after being treated with conventional synthetic DMARDs. These patients were treated according to a treat-to-target (T2T) strategy for one year. The Disease Activity Score in 28 joints-erythrocyte sedimentation rate (DAS28-ESR) and the HAQ-DI were assessed every three months. We also evaluated joint destruction using a modified total Sharp score at baseline and at one year. HAQ-DI progression was defined as the yearly progression of HAQ-DI >0.1. We performed a multiple logistic regression analysis to explore the factors predicting HAQ-DI progression at one year. RESULTS: HAQ-DI progression was observed in 18% of the patients. The multiple logistic regression analysis revealed the independent variables associated with HAQ-DI progression were: DAS28-ESR >5.1 at baseline (odds ratio [OR] 0.31, 95% con dence interval [CI] 0.13-0.74, p=0.0083); HAQ-DI score at baseline <0.5 (OR 2.27, 95% CI 1.22-4.26, p=0.0102); and achievement of low disease activity at 12 weeks (OR 0.42, 95% CI 0.21-0.82, p=0.0112). CONCLUSIONS: Our data suggest that maintaining clinical improvement according to T2T and initiating the treatment at an early stage are important for functional improvement after one year and that patients with low baseline HAQ scores have a higher risk of HAQ disability progression.
AB - OBJECTIVES: To determine prognostic factors for the Health Assessment Questionnaire-Disability Index (HAQ-DI) progression in patients with rheumatoid arthritis (RA) in clinical practice. METHODS: We evaluated 388 biological disease-modifying anti-rheumatic drug (bDMARD)-naïve Japanese patients with RA with moderate to high disease activity at study entry after being treated with conventional synthetic DMARDs. These patients were treated according to a treat-to-target (T2T) strategy for one year. The Disease Activity Score in 28 joints-erythrocyte sedimentation rate (DAS28-ESR) and the HAQ-DI were assessed every three months. We also evaluated joint destruction using a modified total Sharp score at baseline and at one year. HAQ-DI progression was defined as the yearly progression of HAQ-DI >0.1. We performed a multiple logistic regression analysis to explore the factors predicting HAQ-DI progression at one year. RESULTS: HAQ-DI progression was observed in 18% of the patients. The multiple logistic regression analysis revealed the independent variables associated with HAQ-DI progression were: DAS28-ESR >5.1 at baseline (odds ratio [OR] 0.31, 95% con dence interval [CI] 0.13-0.74, p=0.0083); HAQ-DI score at baseline <0.5 (OR 2.27, 95% CI 1.22-4.26, p=0.0102); and achievement of low disease activity at 12 weeks (OR 0.42, 95% CI 0.21-0.82, p=0.0112). CONCLUSIONS: Our data suggest that maintaining clinical improvement according to T2T and initiating the treatment at an early stage are important for functional improvement after one year and that patients with low baseline HAQ scores have a higher risk of HAQ disability progression.
UR - http://www.scopus.com/inward/record.url?scp=85097571369&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097571369&partnerID=8YFLogxK
M3 - Article
C2 - 32896260
AN - SCOPUS:85097571369
SN - 0392-856X
VL - 38
SP - 1096
EP - 1101
JO - Clinical and Experimental Rheumatology
JF - Clinical and Experimental Rheumatology
IS - 6
ER -